FGP
ORKA

Freestone Grove Partners’s Oruka Therapeutics ORKA Stock Holding History

Freestone Grove Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13M Buy
+22,421
New +$1.49M 0.01% 415

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Freestone Grove Partners's ORKA Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 22,421 shares worth $2.13M. The stake represents 0.01% of the portfolio and ranks #415 among its holdings.

255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Freestone Grove Partners held 22,421 shares of Oruka Therapeutics worth $2.13M as of Q2 2026.
  • Oruka Therapeutics was a new Freestone Grove Partners position in Q2 2026.
  • Oruka Therapeutics made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #415 holding.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.